Thromboembolic Complications in Mild Covid-19 Cases

Thromboembolic Complications Post-COVID-19: What is the Risk in Mild-Moderate Cases?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06695377

Enrollment

961

Registered

2024-11-19

Start date

2022-01-01

Completion date

2022-09-30

Last updated

2024-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID 19, Post COVID-19, Thromboembolic and Bleeding Complications, Thromboembolism, Venous

Keywords

COVID 19, thromboembolism, thromboembolic complications, pulmonary embolism, deep venous thrombosis

Brief summary

The aim of the study is to investigate the frequency of thromboembolic complications and the factors influencing them in COVID-19 cases that did not require hospitalization. For this purpose, patients registered at two different family health centers in Istanbul were retrospectively screened, and their status regarding post-COVID-19 thromboembolic events was recorded. The sociodemographic characteristics, medical history, COVID-19 treatments received, comorbidities, and current medications of all patients were examined and compared with the occurrence of complications.

Detailed description

Studies on COVID-19 complications in the literature have predominantly focused on patients treated in hospitals, particularly in intensive care units. Data on patients with mild to moderate symptoms who were followed up on an outpatient basis in primary care are quite limited. Therefore, our research investigated the incidence of thrombotic events within six months following infection in mild to moderate COVID-19 cases and the factors that might influence these events. Records of 961 individuals registered at two different family health centers in Istanbul were reviewed. Patients were contacted by phone, informed about the study, and data regarding their sociodemographic characteristics, medical histories, COVID-19 infection experiences, and medications used were collected. Comparative analyses (Fisher's exact test) and logistic regression tests were conducted.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Being over 18 years of age * Having had a confirmed COVID-19 infection verified by a PCR test * Being monitored at a family health center without requiring hospitalization during the COVID-19 course * Having at least 6 months elapsed since the infection * Availability of the patient's medical records * Absence of any language barrier or health issue that would prevent communication with the patient

Exclusion criteria

* Being under 18 years of age * Having had less than 6 months since the COVID-19 infection * Presence of any condition that prevents communication with the patient * Incomplete or missing medical records of the patient * History of hospitalization due to COVID-19 infection

Design outcomes

Primary

Measure	Time frame	Description
The frequency of thromboembolic complications in COVID-19 patients not requiring hospitalization.	january-june 2022	Patients registered at a family health center were retrospectively reviewed, and those with a history of COVID-19 PCR positivity who had been followed up as outpatients were included. The occurrence of venous or arterial thromboembolism within the first 6 months after infection was recorded from their medical reports, and the frequency was calculated.
The relationship between patients' comorbidities and the occurrence of thromboembolic events post-COVID.	january-june 2022	The patients' existing chronic conditions from the time of their COVID-19 infection were recorded by reviewing the family medicine system. The presence of chronic diseases was then analyzed in comparison to the occurrence of thrombosis within the first 6 months following COVID-19 infection.
The relationship between patients' medications and the occurrence of thromboembolic events post-COVID.	january-june 2022	The medications regularly used by patients for their chronic conditions since the time of their COVID-19 infection were noted by reviewing records in the family medicine system. These medications were then analyzed in comparison to the occurrence of thrombosis within the first 6 months following COVID-19 infection.

Countries

Turkey (Türkiye)

Outcome results